09
Jun
2009
Posted in I - Series B, Q - 2Q09, R - MID WEST, X - Diabetes, XX - MI
Metabolic Solutions Development (Kalamazoo, MI) a clinical-stage biopharmaceutical company focused on Type II diabetes, closed a $9.5M Series B financing. Participants include Southwest Michigan First Life Science Fund and Hopen Therapeutics.